Tag: immunotherapy

Modulight Spotlights: LASER-SHARP RESEARCH – May 2026

Laser-sharp Research / immunology, immunotherapy, laser-sharp research, light activation, liposomes, ML6600, pancreatic cancer, Photoimmunotherapy / May 20, 2026

Modulight Spotlights: LASER-SHARP RESEARCH – May 2026 The research spotlight goes this month to Nimit Shah and the team from Dr. Girgis Obaid’s Lab Molecular Imaging and Optical Nanotherapeutics at University of Texas, Dallas. They developed and evaluated light-activated, verteporfin-containing liposomes for pancreatic cancer. This cancer is notoriously difficult to treat and more effective therapies are [...]

Modulight Spotlights: LASER-SHARP RESEARCH – May 2026 Read More »

Modulight Spotlights: LASER-SHARP RESEARCH – April 2026

Laser-sharp Research / 689 nm, cancer, immunotherapy, IR700, laser therapy, laser-sharp research, ML7710, peptides, Photoimmunotherapy, targeted therapies, tumor / April 27, 2026

Modulight Spotlights: LASER-SHARP RESEARCH – April 2026 This month we are pleased to highlight new interesting article by Naoya Kondo and the team at Kansai Medical University in Japan. They developed a cancer cell-targeted photoimmunotherapy compound consisting of IR700 photoabsorber conjugated to bicyclic peptide. Use of small peptide could speed drug clearance from the body

Modulight Spotlights: LASER-SHARP RESEARCH – April 2026 Read More »

Modulight Spotlights: LASER-SHARP RESEARCH – October 2025

Laser-sharp Research / breast cancer, immunotherapy, laser-sharp research, ML7710, myeloma, oral cancer, Photoimmunotherapy, preclinical, T cells / October 29, 2025

This month we are highlighting exciting findings by S. Takao et al. from Hisataka Kobayashi’s lab at the National Cancer Institute, NIH. Published in Cancer Letters, the study shows that near-infrared photoimmunotherapy can destroy cancer cells by targeting intercellular adhesion molecule-1.

Modulight Spotlights: LASER-SHARP RESEARCH – October 2025 Read More »

Modulight Spotlights: LASER-SHARP RESEARCH – September 2025

Laser-sharp Research / cancer, immunotherapy, in vitro, in vivo, laser-sharp research, ML7710, noveltherapies, Photoimmunotherapy, targeted therapy / September 2, 2025

Published in journal Cancer Medicine, the study shows that the therapeutic effect of photoimmunotherapy is highly dependent on the used light irradiation conditions. Application of the ML7710 medical laser at different durations and powers resulted in highest anti-tumor effect with increased light dose but lowering fluence rate below what is currently used in clinic.

Modulight Spotlights: LASER-SHARP RESEARCH – September 2025 Read More »

Modulight Spotlights: LASER-SHARP RESEARCH – August 2025

Laser-sharp Research / breast cancer, cancer, immunotherapy, in vitro, in vivo, laser-sharp research, ML7710, NIH, Photoimmunotherapy, targeted therapy / August 18, 2025

Laser-sharp research of the month is by Furusawa et al. at Center for Cancer Research, National Cancer Institute, USA. The discovery, published in Annals of Medicine, showed the potential of photoimmunotherapy for treating breast cancer. To expand the usefulness of photoimmunotherapy outside the clinically approved head & neck indication, the new therapy targeted epithelial cell adhesion molecule in breast cancer.

Modulight Spotlights: LASER-SHARP RESEARCH – August 2025 Read More »

Modulight Spotlights: LASER-SHARP RESEARCH – March 2025

Laser-sharp Research / bladder cancer, cancer, Cancer therapy, immune activation, immune response, immunotherapy, laser-sharp research, Memorial Sloan Kettering Cancer Center, ML7710, padeliporfin / March 19, 2025

Coleman et al. / MSKCC developed a vascular-targeted therapy for bladder cancer. Padeliporfin is illuminated with the Modulight’s ML7710 laser, resulting in selective ablation of bladder tumors, without harming the healthy bladder tissue.

Modulight Spotlights: LASER-SHARP RESEARCH – March 2025 Read More »

Modulight Spotlights: LASER-SHARP RESEARCH – February 2025

Laser-sharp Research / breast cancer, cancer, Cancer therapy, cancer treatment, immunology, immunotherapy, in vitro, in vivo, laser-sharp research, ML6600, photosensitizer, research, tumor, verteporfin / February 17, 2025

A. Lepland and the teams at University of Tartu, Estonia and Veneto Institute of Oncology, Italy, developed a new immunotherapy for triple negative breast cancer, using Modulight ML6000-series laser. Tumor growth slowed down and the cancer’s spreading to the lungs was suppressed.

Modulight Spotlights: LASER-SHARP RESEARCH – February 2025 Read More »

Peptide-Drug Conjugate for Therapeutic Reprogramming of Tumor-Associated Macrophages in Breast Cancer

Scientific papers / 689 nm, breast cancer, immunology, immunotherapy, in vitro, in vivo, ML6600, photosensitizer, tumor, verteporfin / January 22, 2025

Published in: Advanced Science Authors: Anni Lepland, Elisa Peranzoni, Uku Haljasorg, Eliana K. Asciutto, Maria Crespí-Amer, Lorenzo Modesti, Kalle Kilk, Manuel Lombardia, Gerardo Acosta, Miriam Royo, Pärt Peterson, Ilaria Marigo, Tambet Teesalu, Pablo Scodeller

Peptide-Drug Conjugate for Therapeutic Reprogramming of Tumor-Associated Macrophages in Breast Cancer Read More »

Modulight Spotlights: LASER-SHARP RESEARCH – January 2025

Laser-sharp Research / cancer, immunology, immunotherapy, in vitro, in vivo, laser-sharp research, LaserSharpResearch, light activation, ML7710, research, targeted therapies / January 22, 2025

Kobayashi et al. at NIH developed a therapy which results in tumor cell membrane destruction and immunogenic cell death. When activated with the ML7710 laser, there was proven efficacy against various cancer cell types including pancreatic, oral, breast, and ovarian cancer.

Modulight Spotlights: LASER-SHARP RESEARCH – January 2025 Read More »